PPARA and cancer: This hypothesis is also applicable to CD8+ T cells, as synergistic antitumor effects of combined PD-1 blockade and PPARα agonism (i.e. by fenofibrate or bezafibrate) are observed in several cancer models, including colon carcinoma, melanoma, and lung carcinoma [69, 92–94].